Reports
Sale
Generalized Anxiety Disorder Market Size, Growth, Forecast: By Therapeutic Type: Antidepressant, Buspirone, Benzodiazepines; By Therapy Type: Interpersonal Therapy, Behavior Therapy, Cognitive Behavioral Therapy, Mindfulness Based Cognitive Therapy; By Diagnosis; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Generalized Anxiety Disorder Market Outlook
The generalized anxiety disorder market size in the 7 major markets was valued at USD 1717.5 million in 2023, driven by the increasing advancements in psychotherapeutic as well as pharmacological treatment options for patients. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to rise from USD 1809.8 million in 2024 to USD 2751.1 million by 2032.
Generalized Anxiety Disorder: Introduction
Generalized anxiety disorder (GAD) is marked by persistent feelings of tension and worry that do not seem to go away. Common symptoms include trembling, twitching, trouble falling or staying asleep, sweating, tense muscles, nausea, and trouble breathing, among others. Medicines, counselling, lifestyle changes, and relaxation techniques are some of the common methods used to treat GAD. It may also worsen or instigate other physical conditions, such as insomnia, irritable bowel syndrome, headaches, and migraines.
Generalized Anxiety Disorder Market Analysis
The generalized anxiety disorder market demand is driven by the modern fast paced lifestyles that induce high stress levels in the people. With rising incidence of the condition, there has been heightened awareness and education about addressing mental health issues with proper care. Rapid advancements have been made in diagnostic and screening methods to offer proper treatment to patients.
Conventionally, pharmacological treatment alternatives like duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine have been used in the market. However, with rising technological advancements in drug development, researchers have developed a non-sedating drug treatment for GAD. BNC210 is a newly developed drug that reduces anxiety by working on cholinergic, a different chemical system in the brain essential in forming memories and signalling uncertainty.
In April 2023, Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. collaborated to initiate a phase II and III clinical study for Ulotaront, a potential treatment for generalized anxiety disorder (GAD). The rising drug developments using a diverse set of approaches to cater to a wider audience are also expected to impact the generalized anxiety disorder market value positively in the forecast period.
Apart from pharmaceuticals, psychological interventions like cognitive behavioural therapy are commonly used to manage GAD.
Generalized Anxiety Disorder Market Segmentation
Market Breakup by Therapeutic Type
- Antidepressant
- Buspirone
- Benzodiazepines
Market Breakup by Therapy Type
- Interpersonal Therapy
- Behavior Therapy
- Cognitive Behavioral Therapy
- Mindfulness Based Cognitive Therapy
Market Breakup by Diagnosis
- Deep Brain Stimulation
- Electroconvulsive Therapy
- Transcranial Magnetic
- Stimulation Vagus Nerve
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Generalized Anxiety Disorder Market Overview
North America holds a significant generalized anxiety disorder market share. Since the population has high awareness of mental health issues, they are more familiar and comfortable with the treatment and management of the disease. The presence of influential pharmaceutical companies keeps working on new drug formulations for patient welfare.
With a well-equipped medical infrastructure, Europe is another major market for GAD. With higher research and academic institutions, the number of product launches and clinical trials occurring in the region is higher. Regulatory frameworks, like the European Medicine Agency, also play a pivotal role in maintaining the efficacy of drug therapies.
The Asia Pacific region is witnessing expediated generalized anxiety disorder market growth due to declining stigmas associated with mental health issues. With increasing urbanisation and changing lifestyles, stress related issues have grown in the people residing in the region. With a vision to address such issues properly, several private and government institutions have partnered to impart education on the same.
Generalized Anxiety Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eli Lilly and Company
- GlaxoSmithKline Pharmaceuticals Limited
- Pfizer, Inc.
- Abbott Laboratories
- Bristol-Myers Squibb
- Actavis Pharmaceutical Company
- F. Hoffmann-La Roche
- Sumitomo Dainippon Pharma
- MindMed
- VistaGen Therapeutics, Inc
- Mitsubishi Chemical Group Corporation
- Sanofi
- Mitsubishi Chemical Group Corporation
- Forest Laboratories, Inc
- H. Lundbeck A/S
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Type |
|
| Breakup by Therapy Type |
|
| Breakup by Diagnosis |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Generalized Anxiety Disorder Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Generalized Anxiety Disorder Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.1 Germany Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.2 France Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.3 Italy Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.4 Spain Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.4 Japan Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
6 Generalized Anxiety Disorder Market Overview – 7MM
6.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
6.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
7 Generalized Anxiety Disorder Market Landscape – 7MM
7.1 Generalized Anxiety Disorder: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Generalized Anxiety Disorder Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Treatment Type
8 Generalized Anxiety Disorder Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Generalized Anxiety Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Generalized Anxiety Disorder Market Segmentation – 7MM
11.1 Generalized Anxiety Disorder Market by Therapeutic Type
11.1.1 Market Overview
11.1.2 Antidepressant
11.1.3 Buspirone
11.1.4 Benzodiazepines
11.2 Generalized Anxiety Disorder Market by Therapy Type
11.2.1 Market Overview
11.2.2 Interpersonal Therapy
11.2.3 Behavior Therapy
11.2.4 Cognitive Behavioral Therapy
11.2.5 Mindfulness Based Cognitive Therapy
11.3 Generalized Anxiety Disorder Market by Diagnosis
11.3.1 Market Overview
11.3.2 Deep Brain Stimulation
11.3.3 Electroconvulsive Therapy
11.3.4 Transcranial Magnetic
11.3.5 Stimulation Vagus Nerve
11.4 Generalized Anxiety Disorder Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Generalized Anxiety Disorder Market
12.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
12.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
12.3 Generalized Anxiety Disorder Market by Disease Type
12.4 Generalized Anxiety Disorder Market by Treatment Type
13 EU-4 and United Kingdom Generalized Anxiety Disorder Market
13.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
13.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
13.3 Germany Generalized Anxiety Disorder Market Overview
13.3.1 Generalized Anxiety Disorder Market by Disease Type
13.3.2 Generalized Anxiety Disorder Market by Treatment Type
13.4 France Generalized Anxiety Disorder Market Overview
13.4.1 Generalized Anxiety Disorder Market by Disease Type
13.4.2 Generalized Anxiety Disorder Market by Treatment Type
13.5 Italy Generalized Anxiety Disorder Market Overview
13.5.1 Generalized Anxiety Disorder Market by Disease Type
13.5.2 Generalized Anxiety Disorder Market by Treatment Type
13.6 Spain Generalized Anxiety Disorder Market Overview
13.6.1 Generalized Anxiety Disorder Market by Disease Type
13.6.2 Generalized Anxiety Disorder Market by Treatment Type
13.7 United Kingdom Generalized Anxiety Disorder Market Overview
13.7.1 Generalized Anxiety Disorder Market by Disease Type
13.7.2 Generalized Anxiety Disorder Market by Treatment Type
14 Japan Generalized Anxiety Disorder Market
14.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
14.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
14.2.1 Generalized Anxiety Disorder Market by Disease Type
14.2.2 Generalized Anxiety Disorder Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Eli Lilly and Company
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 GlaxoSmithKline Pharmaceuticals Limited
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Pfizer, Inc.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Abbott Laboratories
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Bristol-Myers Squibb
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Actavis Pharmaceutical Company
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 F. Hoffmann-La Roche
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Sumitomo Dainippon Pharma
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 MindMed
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 VistaGen Therapeutics, Inc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Mitsubishi Chemical Group Corporation
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Sanofi
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Mitsubishi Chemical Group Corporation
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Forest Laboratories, Inc
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 H. Lundbeck A/S
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Generalized Anxiety Disorder Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1717.5 million in 2023 in the 7 major markets. The growth is driven by the rising advancements in psychotherapeutic and pharmacological treatment alternatives.
The market is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, likely to reach a market value of USD 2751.1 million by 2032.
The market demand is driven by the declining stigma around mental health issues across the 7 major markets. The efforts to offer easy accessibility of mental health services is another essential factor.
The current market trend revolves around using non-sedative drugs to treat GAD in patients. BNC210 is a newly developed drug that reduces anxiety by working on a different chemical system in the brain essential in forming memories and signalling uncertainty.
Based on therapy types, the market is divided into interpersonal therapy, behavior therapy, cognitive behavioral therapy, and mindfulness based cognitive therapy.
Antidepressant, buspirone and benzodiazepines are common therapeutic types available in the market.
Deep brain stimulation, electroconvulsive therapy, transcranial magnetic, and stimulation vagus nerve are the different types of diagnosis.
The major regions of the market include the United States, Japan, and EU-4, which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Sumitomo Dainippon Pharma, MindMed, VistaGen Therapeutics, Inc, Mitsubishi Chemical Group Corporation, Sanofi, Forest Laboratories, Inc and H. Lundbeck A/S.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER